홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Arotinolol

HCID 2239
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
52560-77-7
표준 SMILES
CC(C)(C)NCC(O)CSc1nc(-c2ccc(C(N)=O)s2)cs1
InChIKey
BHIAIPWSVYSKJS-UHFFFAOYSA-N
분자식
C15H21N3O2S3
평균 분자량
371.5 g/mol
단동위원소 질량
371.07959044

개요

Arotinolol is a member of thiophenes and an aromatic amide.

이름 및 식별자

우선 이름
Arotinolol
IUPAC
5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide
영어명
AROTINOLOL
분자식
C15H21N3O2S3
분자량
371.54

이름 및 동의어

Arotinolol68377-92-4ArotinololumNSC-317940394E3P3B99DTXSID3022619S-5965-(2-{[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl}-1,3-thiazol-4-yl)thiophene-2-carboxamide5-(2-((3-(tert-butylamino)-2-hydroxypropyl)sulfanyl)-1,3-thiazol-4-yl)thiophene-2-carboxamideRefChem:1141612-(3'-tert-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochlorideDTXCID302619
이름 더 보기
ArotinoloArololArot-APIArottnololNSC 317940Arotinolol (Almarl)Arotinolol free baseAROTINOLOL USP/EP/BPArotinolol Intermediate
5-(2-((3-((1,1-Dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)thiazol-4-yl)thiophene-2-carboxamideArotinolol [INN]Arotinololum [Latin](+-)-Arotinolol5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamideUNII-394E3P3B99MFCD00865895

데이터베이스 식별자

CAS
52560-77-7、68377-92-4
PubChem CID
2239
DTXSID
DTXSID3022619
ChEMBL
CHEMBL93298
ChEBI
CHEBI:135569
UNII
394E3P3B99
Nikkaji
J239.627K

물성

구조 계산 물성보충 중

XLogP
2.3
극성 표면적
170 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
7
회전 가능 결합 수
8
무거운 원자 수
23
형식 전하
0
복잡도
406

실험 및 물리화학적 성질

SolubilitySlightly soluble
Boiling Point599ºC at 760 mmHg
Melting Point149-153ºC

물리화학적 성질

녹는점
148 · 148-149°
끓는 점
599.8 · 599.8±60.0 °C(Predicted)
밀도
1.35 · 1.35
저장 조건
2 · 2-8°C(protect from light)
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
산도 계수 (pKa)
13.71 · 13.71±0.20(Predicted)
물리적 상태
고체
색상
황백색에서 연한 노란색

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

화학 및 산업

약리 정보

Protein Binding · 1건

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. Arotinolol is highly bound to serum proteins reaching a ratio of the original dose of 95.3% in the form of the R-enantiomer and 84.5% of the S-enantiomer. The presented stereospecificity is thought to be related to the α1-acid glycoprotein.

Pharmacodynamics · 1건

Preclinical studies showed a lack of intrinsic sympathomimetic activities or membrane-establishing properties. It is confirmed that arotinolol presents vasorelaxant activity. This characteristic is also proved to be mainly mediated by its α1-blocking property. In preclinical hypertension trials, there is a specific acute bradycardiac and antihypertensive activity with a pronounced reduction in heart rate. Some reports indicate a delayed development of hypertension when arotinolol is administered daily. Arotinolol has a dose-dependent decrease in cardiac contractility and coronary blood flow as well as an increase in total peripheral resistance. The effects of arotinolol have been confirmed in clinical trials where this drug was able to decrease cardiac index and thus, blood pressure.

Mechanism of Action · 1건

Arotinolol binds to the β1-, β2- and α1- adrenergic receptor sites with a very high affinity. Radioligand studies have shown that arotinolol presents a higher affinity to the β-receptor compared to the α-receptor. The elucidated mechanism of action seems to be the result of a reduction in the cardiac output via the β-blockade and an additional inhibition of the counter-regulatory increase in peripheral resistance mediated by the α-blockade.

Biological Half-LifeThe reported half-life of arotinolol is 7.2 hours.
Metabolism/MetabolitesThe stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. The R-enantiomer remains unchanged and it is eliminated from the organism by urine in this form while the S-enantiomer is metabolized.
MeSH Pharmacological Classification · 2건

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Absorption, Distribution and Excretion · 3건

Arotinolol gets rapidly absorbed and distributed in the plasma. The plasma concentration peaks 2 hours after initial administration.

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. Both of the enantiomers were found in urine, suggesting this as the major elimination pathway. It is possible to find arotinolol in urine 2-4 hours after initial administration.

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. The S-enantiomer is highly retained in red blood cells. The distribution studies have shown that arotinolol is mainly distributed from the plasma to the liver followed by the lungs and lastly in the heart. The distribution in the liver was independent on the stereochemistry of the molecules.

상·하류 제품 정보

상류 원료

수산화나트륨